Predictors of impaired bone health in long-term survivors after allogeneic stem cell transplantation

被引:15
作者
Baumgartner, Annic [1 ]
Moesch, Michele [1 ,2 ]
Zumsteg, Melanie [1 ,2 ]
Struja, Tristan [1 ]
Bernet, Selina [1 ]
Medinger, Michael [3 ]
Mueller, Beat [1 ,2 ]
Passweg, Jakob [3 ]
Bargetzi, Mario [4 ]
Schuetz, Philipp [1 ,2 ]
机构
[1] Kantonsspital Aarau, Clin Endocrinol Metab Clin Nutr, Med Univ Dept, Aarau, Switzerland
[2] Univ Basel, Med Fac, Basel, Switzerland
[3] Univ Hosp Basel, Div Hematol, Basel, Switzerland
[4] Kantonsspital Aarau, Med Univ Clin, Div Hematol, Aarau, Switzerland
基金
瑞士国家科学基金会;
关键词
CONSENSUS DEVELOPMENT PROJECT; VERSUS-HOST-DISEASE; FRACTURE RISK; MARROW TRANSPLANTATION; MINERAL DENSITY; CLINICAL-TRIALS; FEMORAL-NECK; OSTEOPOROSIS; PREVENTION; MANAGEMENT;
D O I
10.1038/s41409-019-0484-6
中图分类号
Q6 [生物物理学];
学科分类号
071011 ;
摘要
Survival after allogeneic stem cell transplantation (allo-HSCT) has improved, but so have long-term sequelae. We studied risk factors for fractures and impaired bone health in allo-HSCT patients in the Basel HSCT registry from 01/2003 to 12/2014 using cox proportional models adjusted for age, gender and Karnofsky Index. Our primary endpoint was the incidence of fractures. Out of 652 patients, 32 (5.0%) had a new fracture after transplantation (yearly incidence rate of 1.6%, 95% Confidence Interval [95% CI] 1.1-2.3%) and 325 (49.8%) had low bone mineral density (yearly incidence rate of 13.1%, 95% CI 11.6-14.8%), including 36.0% with osteopenia and 13.8% with osteoporosis. We found vitamin D deficiency during follow-up (Hazard Ratio [HR] 1.25, 95% CI 1.11-1.41, p < 0.001), hyperthyroidism before transplantation (HR 4.85, 95% CI 1.05-22.54, p = 0.044), cumulative years of immunosuppressant exposure (HR 1.23, 95% CI 1.07-1.41, p = 0.004 for steroidal and HR 1.09, 95% CI 1.01-1.18, p = 0.025 for non-steroidal drugs) and graft-versus-host disease (acute HR 1.24, 95% CI 1.11-1.40, p < 0.001; chronic HR 2.82, 95% CI 1.12-7.13, p = 0.028) to be significantly associated with fractures. Patients undergoing HSCT are at increased risk of fractures, which is associated with various disease and treatment-specific factors. Early identification of patients at risk may help to improve preventive measures.
引用
收藏
页码:1651 / 1661
页数:11
相关论文
共 28 条
[1]   Factors influencing the late phase of recovery after bone mineral density loss in allogeneic stem cell transplantation survivors [J].
Anandi, P. ;
Jain, N. A. ;
Tian, X. ;
Wu, C. O. ;
Pophali, P. A. ;
Koklanaris, E. ;
Ito, S. ;
Savani, B. N. ;
Barrett, J. ;
Battiwalla, M. .
BONE MARROW TRANSPLANTATION, 2016, 51 (08) :1101-1106
[2]   Allogeneic bone marrow transplantation is associated with a preferential femoral neck bone loss [J].
Buchs, N ;
Helg, C ;
Collao, C ;
Chapuis, B ;
Slosman, D ;
Bonjour, JP ;
Rizzoli, R .
OSTEOPOROSIS INTERNATIONAL, 2001, 12 (10) :880-886
[3]   National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report [J].
Filipovich, AH ;
Weisdorf, D ;
Pavletic, S ;
Socie, G ;
Wingard, JR ;
Lee, SJ ;
Martin, P ;
Chien, J ;
Przepiorka, D ;
Couriel, D ;
Cowen, EW ;
Dinndorf, P ;
Farrell, A ;
Hartzman, R ;
Henslee-Downey, J ;
Jacobsohn, D ;
McDonald, G ;
Mittleman, B ;
Rizzo, JD ;
Robinson, M ;
Schubert, M ;
Schultz, K ;
Shulman, H ;
Turner, M ;
Vogelsang, G ;
Flowers, MED .
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2005, 11 (12) :945-956
[4]   Significant and persistent loss of bone mineral density in the femoral neck after haematopoietic stem cell transplantation: long-term follow-up of a prospective study [J].
Gandhi, MK ;
Lekamwasam, S ;
Inman, I ;
Kaptoge, S ;
Sizer, L ;
Love, S ;
Bearcroft, PW ;
Milligan, TP ;
Price, CP ;
Marcus, RE ;
Compston, JE .
BRITISH JOURNAL OF HAEMATOLOGY, 2003, 121 (03) :462-468
[5]   An individualised risk-adapted protocol of pre-and post transplant zoledronic acid reduces bone loss after allogeneic stem cell transplantation: results of a phase II prospective trial [J].
Grigg, A. ;
Butcher, B. ;
Khodr, B. ;
Bajel, A. ;
Hertzberg, M. ;
Patil, S. ;
D'Souza, A. B. ;
Ganly, P. ;
Ebeling, P. ;
Wong, E. .
BONE MARROW TRANSPLANTATION, 2017, 52 (09) :1288-1293
[6]   Intermittent Zoledronic Acid Prevents Bone Loss in Adults after Allogeneic Hematopoietic Cell Transplantation [J].
Hari, Parameswaran ;
DeFor, Todd E. ;
Vesole, David H. ;
Bredeson, Christopher N. ;
Burns, Linda J. .
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2013, 19 (09) :1361-1367
[7]   National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group Report [J].
Jagasia, Madan H. ;
Greinix, Hildegard T. ;
Arora, Mukta ;
Williams, Kirsten M. ;
Wolff, Daniel ;
Cowen, Edward W. ;
Palmer, Jeanne ;
Weisdorf, Daniel ;
Treister, Nathaniel S. ;
Cheng, Guang-Shing ;
Kerr, Holly ;
Stratton, Pamela ;
Duarte, Rafael F. ;
McDonald, George B. ;
Inamoto, Yoshihiro ;
Vigorito, Afonso ;
Arai, Sally ;
Datiles, Manuel B. ;
Jacobsohn, David ;
Heller, Theo ;
Kitko, Carrie L. ;
Mitchell, Sandra A. ;
Martin, Paul J. ;
Shulman, Howard ;
Wu, Roy S. ;
Cutler, Corey S. ;
Vogelsang, Georgia B. ;
Lee, Stephanie J. ;
Pavletic, Steven Z. ;
Flowers, Mary E. D. .
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2015, 21 (03) :389-401
[8]   Development and use of FRAXA® in osteoporosis [J].
Kanis, J. A. ;
McCloskey, E. V. ;
Johansson, H. ;
Oden, A. ;
Stroem, O. ;
Borgstroem, F. .
OSTEOPOROSIS INTERNATIONAL, 2010, 21 :407-413
[9]  
Karnofsky DA., 1949, EVALUATION CHEMOTHER, P191
[10]   Risk of osteoporosis and pathologic fractures in cancer patients who underwent hematopoietic stem cell transplantation: a nationwide retrospective cohort study [J].
Lin, Jiun-Nong ;
Chen, Hsuan-Ju ;
Yang, Chih-Hui ;
Lai, Chung-Hsu ;
Lin, Hsi-Hsun ;
Chang, Chao-Sung ;
Liang, Ji-An .
ONCOTARGET, 2017, 8 (21) :34811-34819